{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CMV+pp65+peptide",
    "query": {
      "intervention": "CMV pp65 peptide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CMV+pp65+peptide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T22:22:52.478Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04963413",
      "title": "RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 6,
      "start_date": "2022-01-13",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04963413"
    },
    {
      "nct_id": "NCT02366728",
      "title": "DC Migration Study for Newly-Diagnosed GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Astrocytoma, Grade IV",
        "Giant Cell Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Unpulsed DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "111In-labeled DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-10-12",
      "completion_date": "2020-10-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02366728"
    },
    {
      "nct_id": "NCT00499577",
      "title": "Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "CMV pp65 peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hTERT I540/R572Y/D988Y multipeptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pneumococcal polyvalent vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "survivin Sur1M2 peptide vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Maryland Greenebaum Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 56,
      "start_date": "2006-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499577"
    },
    {
      "nct_id": "NCT02529072",
      "title": "Nivolumab With DC Vaccines for Recurrent Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Astrocytoma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "nivolumab",
          "type": "DRUG"
        },
        {
          "name": "DC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gary Archer Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2016-01",
      "completion_date": "2019-12-30",
      "has_results": true,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02529072"
    },
    {
      "nct_id": "NCT00626483",
      "title": "Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasms Brain"
      ],
      "interventions": [
        {
          "name": "RNA-loaded dendritic cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "basiliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gary Archer Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 34,
      "start_date": "2007-04-24",
      "completion_date": "2016-07-06",
      "has_results": false,
      "last_update_posted_date": "2021-03-09",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00626483"
    },
    {
      "nct_id": "NCT06639607",
      "title": "PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Midline Glioma",
        "Diffuse Midline High-grade Glioma",
        "Medulloblastoma",
        "Ependymoma"
      ],
      "interventions": [
        {
          "name": "PEP-CMV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 68,
      "start_date": "2026-08-31",
      "completion_date": "2051-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Durham, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06639607"
    },
    {
      "nct_id": "NCT00674648",
      "title": "Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "CMV-Peptide-Specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2007-08",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00674648"
    },
    {
      "nct_id": "NCT03615404",
      "title": "Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Malignant Glioma",
        "Medulloblastoma Recurrent",
        "Pediatric Glioblastoma Multiforme",
        "Pediatric Brain Tumor, Recurrent",
        "Pediatric Brain Tumor"
      ],
      "interventions": [
        {
          "name": "CMV-DCs with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td (tetanus toxoid)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gary Archer Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "0 Years to 35 Years"
      },
      "enrollment_count": 11,
      "start_date": "2018-10-05",
      "completion_date": "2020-07-02",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615404"
    },
    {
      "nct_id": "NCT02465268",
      "title": "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioblastoma",
        "Malignant Glioma",
        "Astrocytoma, Grade IV",
        "GBM"
      ],
      "interventions": [
        {
          "name": "pp65-shLAMP DC with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "unpulsed PBMC and saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "pp65-flLAMP DC with GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2016-08-09",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Orlando, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465268"
    },
    {
      "nct_id": "NCT03927222",
      "title": "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Tetanus-Diphtheria Toxoid (Td)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "111-Indium-labeling of Cells for in vivo Trafficking Studies",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-30",
      "completion_date": "2023-02-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-09-04T22:22:52.478Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03927222"
    }
  ]
}